The 301 Hospital (Chinese: 三〇一医院) or People's Liberation Army General Hospital (Chinese: 中国人民解放军总医院), which constitutes simultaneously the PLA Postgraduate Medical School (Chinese: 中国人民解放军医学院), located in Beijing, China, is a military hospital directly subsidiary to Logistic Support Department of the Central Military Commission and the largest general hospital under the auspices of the People's Liberation Army. Its mission includes assuring the health of PLA and China's leaders.

NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Berry Genomics Co., Ltd. engages in the gene detection and sales of equipment and reagents of high-throughput sequencing technology. The genetic testing includes medical products and services, and basic research services. Medical products and services are divided into medical testing services, reagent sales, and equipment sales. Medical testing services are mainly divided into two applications: genetics and oncology. The company was founded on April 14, 1997 and is headquartered in Beijing, China.

Beijing Nuosai Genome Research Center Co., Ltd., established on 1998-09-24, The scope of business includes the development of genetic engineering and bioengineering technologies and products,to develop,Sales;technology development,technology transfer,technical consulting,Technical Services,Technical testing;Biological and genetic analysis instruments,information equipment,Development of Medical Devices,to develop,Sales;Information Consulting;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;software development;Conference Services;selling computers,Software and Auxiliary Equipment;health management,Health Advisory(Except for medical treatment activities subject to approval);Sales of medical devicesIkind,medical instrumentsIIkind;production of medical devicesIkind;Natural science research and experimental development;Medical Research and Experimental Development;Sales No.IIIclass of medical devices;Production No.IIkind,No.IIIclass of medical devices;medical examination medical service.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Production No.IIkind,No.IIIclass of medical devices,Sales No.IIIclass of medical devices,Medical testing and medical services and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

BGI Genomics Co., Ltd. is a holding company that engages in development of science and technology services in genomics field. Its business scope ranges from scientific, health, agricultural and informatics. The company was founded by Wang Jian on September 9, 1999 and is headquartered in Shenzhen, China.

AgResearch offers world-class expertise across a range of science areas. AgResearch is the Crown Research Institute tasked with delivering leading agricultural science and innovation to benefit the wider New Zealand economy. Our internationally-recognised scientists work across the agricultural sectors in collaboration with a range of stakeholders both nationally and internationally, putting science and innovation at the forefront.

Tianjin Jiankang Huamei Medical Diagnostic Technology Co., Ltd., established on 2014-12-11, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;R&D and application of cell technology;Medical Research and Experimental Development;Development of Human Gene Diagnosis and Therapy Technology;Sales of Class II Medical Devices;Sales of Class I Medical Devices;Production of Class I Medical Devices;software development;Information system integration service;Information Technology Consulting Services;Artificial intelligence basic resources and technology platform;Artificial intelligence application software development;Information Consulting Service(Not including licensing information consulting services);Conference and Exhibition Services;Educational Consulting Services(Education and training activities that do not include licensing approval);Health Consulting Services(Does not include medical services);Machinery and Equipment Leasing;Medical equipment rental.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:medical service;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Technology Import and Export;Inspection and testing service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

A&L Canada Laboratories, Inc., part of Deveron Corp., is a Canadian company located in London, ON, that provides testing laboratory services. It was founded by Greg Patterson, he is currently the CEO of the firm. Deveron Corp. acquired A&L Canada Laboratories, Inc. from 2736130 Ontario, Inc. on May 24, 2022 for $39.36 million.\nThe company says this about itself: We are an innovative, research driven technology company focused on sustainable development. Through leading expertise, modern laboratory facilities and strong customer focus, A&L serves a wide range of industries including Agriculture, Environmental, Food & Pharma -- globally. In Agriculture, A&L provides comprehensive analytical services for soil, plant tissue, feed, fertilizer, and water. A&L’s services also include production recommendations, remote sensing and precision agriculture capabilities. A&L Biological Inc. is a subsidiary of A&L Canada Laboratories Inc. focused on research and development of biological compounds for use in agricultural production systems. The Environmental division provides organic and inorganic chemistry and general chemistry using state of the art technology and methodology. For Food & Pharma, A&L provides analytical services for plant tissue, water, media and finished product. A&L’s services also include disease diagnostics, genetic analysis, production recommendations, and Plant Monitoring Program. The company operates two analytical laboratories serving clients throughout Canada, the US and Internationally.

Kikkoman Corp. is a holding company which engages in the food manufacturing business. It operates through the following segments: Domestic Foods-Manufacturing and Sales, Domestic Others, Overseas Foods-Manufacturing and Sales, and Overseas Foods-Wholesale. The Domestic Foods-Manufacturing and Sales segment manufactures and sells soy sauce, beverages, and alcoholic beverages. The Domestic Others segment involves in the production and sale of clinical diagnostic reagents, hygiene inspection agents, processing enzymes and chemical products such as hyaluronic acid. It also operates in real estate property leasing, logistics, and back-office support for Kikkoman Group, and other businesses. The Overseas Foods-Manufacturing and Sales segment sells soy sauce, Del Monte products, and overseas health foods. The Overseas Food-Wholesale segment purchases and sells oriental food products in Japan and overseas. The company was founded on December 7, 1917 and is headquartered in Noda, Japan.

Jiangsu Academy of Agricultural Sciences is a Chinese private company located in Nanjing, with subsidiaries in China, that engages in agriculture research and development.

BL Corp. engages in the development of biopharmaceutical products. The company operates through the following business divisions: Bio-New Treatment and Product. Its products include poly-y-glutamic acid, lactobacillus plantarum BLS41, and skincare products. The company was founded on December 30, 1999 and is headquartered in Yongin-si, South Korea.

Kineta Two LLC operates as a biotechnology company. It develops antiviral programs. The company is headquartered in Seattle, WA.

Amoy Diagnostics is a research and development based diagnostic company focusing on molecular diagnostics for oncology precision medicine. AmoyDx has a portfolio of molecular diagnostic assays. Based on multiple technology platforms including PCR, NGS, FISH and IHC, AmoyDx's core product categories include single gene testing kits, multi-gene testing panels, NGS panels, and NGS analytical systems.

Shanghai Biochip Co., Ltd. (dba ShanghaiBio Corp.) performs specialty R&D services for global pharma/biotech companies. Situated on its own 10-acre campus in the heart of Shanghai's Zhangjiang Hi-Tech Park, China's Bio/Pharma Valley, ShanghaiBio operates in seven buildings totaling 220,000 SQF that contain offices and laboratories.\nIts labs provide GLP/GMP-compliant services and continually undergo rigorous internal and external QA audits. The scientific staff is chiefly home-grown talent trained by professionals schooled in western ways. The company was founded in August 2001 and is headquartered in Shanghai, China.

Kangfang Pharmaceutical Co., Ltd., established on 2017-08-10, Business scope includes medical research and experimental development;R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Chemical product sales(No licensed chemical products);pharmaceutical production;Drug Wholesale;Drug import and export;Import and export;Technology Import and Export

Wankangyuan (Tianjin) Gene Technology Co., Ltd., established on 2015-01-06, The business scope includes genetic medicine related equipment and electronic products,Technology development of computer hardware and software,transfer,Consulting and Services;Health Information Consultation(Except for medical advice);biotechnology development,Technical Services,technology transfer,technical consulting;Conference Services;Exhibition;Computer System Services;Computer hardware and software and auxiliary equipment,Equipment,Instrumentation,Chemical Products(Hazardous chemicals and precursor drugs are excluded),Wujinjiaodian,Machinery sales;Goods and technology import and export business;Pharmaceutical Technology Development,technical consulting,Technical Services,technology transfer.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Bantam Pharmaceutical LLC is a company headquartered in New York, NY, that engages in research and development of oncology drugs. It was founded by Victor F. Keen. Michael T. Stocum has been the CEO since 2019.\nThe company says this about itself: Bantam Pharmaceutical is a drug discovery and development company channeling the power of mitochondrial dynamics to address unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors. Bantam has IND clearance from the US Food and Drug Administration (FDA) for its lead candidate, BTM-3566, in B-cell malignancies.